U.S. Markets closed

iBio, Inc. (IBIO)

NYSE MKT - Nasdaq Real Time Price. Currency in USD
Add to watchlist
0.39+0.00 (+0.46%)
At close: 4:00PM EDT
People also watch

iBio, Inc.

600 Madison Avenue
Suite 1601
New York, NY 10022
United States

Full Time Employees26

Key Executives

Mr. Robert B. KayExec. Chairman and Chief Exec. Officer310.73kN/A77
Mr. Robert L. ErwinPres230kN/A64
Mr. Terence E. Ryan Ph.D.Chief Scientific Officer200kN/A62
Mr. James P. Mullaney CPAChief Financial OfficerN/AN/A46
Mr. Douglas C. HicksSr. VP of Bus. Devel. & StrategyN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


iBio, Inc., a biotechnology company, focuses on commercializing its proprietary plant-based protein expression technologies in the United States and internationally. The company’s proprietary technologies include iBioLaunch, a transformative platform technology for the development and production of therapeutic proteins and vaccines; iBioModulator, a technology platform that is designed to enhance the potency and duration of effect of prophylactic and therapeutic vaccines; and iBio Advanced Technologies. Its therapeutic protein product candidates comprise IBIO-CFB03 for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis, and other fibrotic diseases; C1 esterase inhibitor, a plasma-derived protein; Alpha-Galactosidase, an enzyme replacement product; and Palivizumab, a monoclonal antibody. The company’s vaccine candidates include H1N1 Influenza and H5N1 Influenza viral disease vaccines, which have completed Phase I clinical trials; Yellow Fever viral disease vaccine, which is in preclinical stage; Human Papillomavirus therapeutic vaccine; and malaria and hookworm parasitic pathogen vaccines, which are in Phase I clinical trials. Its biodefense product candidates include Anthrax/Plague bacterial disease vaccine; and Anthrax, a monoclonal antibody. The company has a collaboration agreement with Fraunhofer Center for Molecular Biology to perform research and development activities to develop the recombinant form of C1 esterase inhibitor. It also has a collaboration and license agreement with FioCruz for the use of its proprietary technology in connection with the development, manufacture, and commercialization of vaccines; and a license and collaboration agreement with Caliber Biotherapeutics LLC to use its iBioLaunch platform in connection with the development of an undisclosed monoclonal antibody-based therapeutic protein for an oncology indication. iBio, Inc. is based in New York, New York.

Corporate Governance

iBio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.